Pancreatic anaplastic carcinoma (PAC) is a rare entity (2-7% of pancreatic carcinomas), with a mean survival of 5.7 months. We present the case of a 44-year-old patient who consulted for upper gastroin-testinal bleeding and was admitted hemodynamically unstable. CT showed a large mass in the gastric fundus with infiltration to the pancreas, suggestive of GIST. Esophagogastroduodenoscopy identified a submucosal ulcerated lesion that was intractable by this means. An emergency surgical resection was performed, and the histology confirmed a PAC. The patient evolved favorably, without recurrence after 5 years post adjuvant chemotherapy. Treatment with radical surgery plus adjuvant chemotherapy was effective.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.4067/s0034-98872024001001092 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Primary cutaneous/subcutaneous Ewings sarcoma.
Bull Cancer
March 2025
Pediatric Oncology, insitut Gustave-Roussy, Villejuif, France. Electronic address:
Amongst Ewing sarcoma family of tumours, (EFST), cutaneous/subcutaneous Ewing sarcoma are defined as tumours arising from cutaneous or subcutaneous tissue, not invading the underlying aponeurosis. They are rare tumours, with less than 200 patients published. They are typically small tumours (less than 5cm), and can arise at any anatomical location, with a particular tropism for distal, truncal and head/neck locations, compared to classical Ewing sarcoma.
View Article and Find Full Text PDFRole of neoadjuvant chemo-radiotherapy for resectable and borderline resectable pancreatic adenocarcinoma- A systematic review and meta-analysis.
Int J Radiat Oncol Biol Phys
March 2025
Department of Radiation Oncology, Taipei Medical University Hospital, Taipei, Taiwan; National Institute of Cancer Research, National Health Research Institutes, Miaoli, Taiwan; Department of Oncology, College of Medicine, National Cheng Kung University, Tainan, Taiwan. Electronic address:
Background: Randomized trials and meta-analyses have indicated longer survival with neoadjuvant than with adjuvant therapy in patients with resectable or borderline resectable (R/BR) pancreatic adenocarcinoma. Despite the efficacy of chemotherapy, the role of radiotherapy as an adjuvant or neoadjuvant treatment for patients with R/BR pancreatic adenocarcinoma remains unclear. In this systematic review and meta-analysis, we compared the benefits of additional chemoradiotherapy (CRT) to neoadjuvant chemotherapy (NAC) with NAC alone for R/BR pancreatic adenocarcinoma.
View Article and Find Full Text PDF[Perforation of Small Intestinal Gastrointestinal Stromal Tumor Required Emergency Surgery-A Case Report].
Gan To Kagaku Ryoho
February 2025
Dept. of Surgery, Chiba Tokushukai Hospital.
The case was a 77-year-old man. He presented with abdominal pain and melena to our hospital. Abdominal CT showed thickening of the small intestinal wall and findings of intraperitoneal free air.
View Article and Find Full Text PDFPlant polyphenols in gastric cancer: Nature's healing touch.
Semin Oncol
March 2025
Division of Gastroenterology, Charleston Area Medical Center/CAMC Institute for Academic Medicine Program, Charleston, WV, USA.
Globally, gastric cancer ranks as the fifth most common cancer and is the third most common cause of malignancy-associated mortality. Although surgery is the primary treatment option for gastric cancer, adjuvant chemotherapy improves survival in patients following surgery. Proverbially, plant polyphenols have many beneficial health effects, including anticancer properties.
View Article and Find Full Text PDFHeterogeneous cellular responses to hyperthermia support combined intraperitoneal hyperthermic immunotherapy for ovarian cancer mouse models.
Sci Transl Med
March 2025
Cancer Biology Research Center (Key Laboratory of the Ministry of Education), Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430000, China.
The benefit of hyperthermic intraperitoneal chemotherapy (HIPEC) in ovarian cancer remains controversial, hindering the development of rational combination therapies based on hyperthermia (HT). This study reports the preliminary results of the neoadjuvant HIPEC (NHIPEC) trial (ChiCTR2000038173), demonstrating enhanced tumor response in high-grade serous ovarian cancer with NHIPEC. Through single-cell RNA sequencing analysis, we identified both homogeneous and heterogeneous cellular responses to HT within the tumor and microenvironment.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!